Comparative acute effects of the calcium channel blockers tiapamil, nisoldipine, and nifedipine on blood pressure and some regulatory factors in normal and hypertensive subjects
- PMID: 2422467
- DOI: 10.1097/00005344-198603000-00011
Comparative acute effects of the calcium channel blockers tiapamil, nisoldipine, and nifedipine on blood pressure and some regulatory factors in normal and hypertensive subjects
Abstract
To clarify the pharmacological profile of the two new calcium channel blockers tiapamil and nisoldipine in humans, their acute effects as compared with those of the reference agent nifedipine were assessed in 10 normal subjects and 10 patients with essential hypertension. Blood pressure (BP), heart rate (HR), plasma and urinary catecholamine, sodium and potassium, plasma renin and aldosterone levels, and urinary prostaglandin E2 and F2 excretion rates were determined before and up to 4 or 5 h (urine values) after intravenous injection of placebo (20 ml 0.9% NaCl), tiapamil 1 mg/kg body weight, nisoldipine 6 micrograms/kg, or nifedipine 15 micrograms/kg. The four studies were performed at weekly intervals according to Latin square design. All three calcium channel blockers significantly (p less than 0.05 or lower) lowered BP and distinctly increased sodium excretion in hypertensive patients, but had only little influence on these parameters in normal subjects. HR was increased in both groups. Changes in BP and HR were maximal at 5 min and largely dissipated 3 h after drug injection. Effects on BP and HR, as well as concomitant mild increases in plasma norepinephrine and renin levels that occurred in both groups, tended to be more pronounced (about double) following nisoldipine than following tiapamil or nifedipine at the dosages given. Plasma aldosterone, epinephrine levels, and prostaglandin excretion rates were not consistently modified. These findings demonstrate that tiapamil and nisoldipine possess distinct antihypertensive properties in humans. Different chronotropic and renin-activating effects of different calcium channel blockers may be determined, at least in part, by a different influence on sympathetic activity.(ABSTRACT TRUNCATED AT 250 WORDS)
Similar articles
-
Nisoldipine. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of angina pectoris, hypertension and related cardiovascular disorders.Drugs. 1988 Dec;36(6):682-731. doi: 10.2165/00003495-198836060-00003. Drugs. 1988. PMID: 3065058 Review.
-
[Hypotensive properties of nisoldipine. Comparative study in essential, renal and renovascular hypertension].Arzneimittelforschung. 1984;34(5):620-3. Arzneimittelforschung. 1984. PMID: 6540581 Clinical Trial. German.
-
Comparison of nisoldipine and atenolol in the treatment of essential hypertension.Arzneimittelforschung. 1989 Mar;39(3):379-82. Arzneimittelforschung. 1989. PMID: 2667523 Clinical Trial.
-
Effects of nisoldipine on sympathetic activity, the renin-angiotensin-aldosterone system, and water-sodium-calcium metabolism in patients with essential hypertension.Arzneimittelforschung. 1989 Jun;39(6):710-4. Arzneimittelforschung. 1989. PMID: 2775339
-
Nisoldipine coat-core. A review of its pharmacology and therapeutic efficacy in hypertension.Drugs. 1996 Aug;52(2):232-53. doi: 10.2165/00003495-199652020-00009. Drugs. 1996. PMID: 8841741 Review.
Cited by
-
Nisoldipine. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of angina pectoris, hypertension and related cardiovascular disorders.Drugs. 1988 Dec;36(6):682-731. doi: 10.2165/00003495-198836060-00003. Drugs. 1988. PMID: 3065058 Review.
-
Calcium channel antagonists. Part III: Use and comparative efficacy in hypertension and supraventricular arrhythmias. Minor indications.Cardiovasc Drugs Ther. 1988 Mar;1(6):625-56. doi: 10.1007/BF02125750. Cardiovasc Drugs Ther. 1988. PMID: 3154329 Review.
-
Comparison of short-acting versus extended-release nifedipine: Effects on hemodynamics and sympathetic activity in patients with stable coronary artery disease.Sci Rep. 2020 Jan 24;10(1):565. doi: 10.1038/s41598-019-56890-1. Sci Rep. 2020. PMID: 31980638 Free PMC article. Clinical Trial.
-
The pharmacology of nisoldipine.Cardiovasc Drugs Ther. 1987 Dec;1(4):393-402. doi: 10.1007/BF02209081. Cardiovasc Drugs Ther. 1987. PMID: 3154674 Review.
-
Calcium channel antagonists. Part V: Second-generation agents.Cardiovasc Drugs Ther. 1988 Jul;2(2):191-203. doi: 10.1007/BF00051234. Cardiovasc Drugs Ther. 1988. PMID: 3154705 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical
Miscellaneous